Drug Profile
BI 831266
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours in Austria (Parenteral, Infusion)
- 01 Apr 2012 BI 831266 is still in phase I trials for Solid tumours
- 19 Aug 2010 Boehringer Ingelheim completes enrolment in its phase I trial [NCT00756223] for Solid tumours in Austria